Successful Treatment with Empirical Erlotinib in a Patient with Respiratory Failure Caused by Extensive Lung Adenocarcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We herein describe a 70-year-old woman who presented with respiratory failure due to extensive lung adenocarcinoma. Despite advanced disease, care in the intensive care unit with ventilator support was performed because she was a newly diagnosed patient and was considered to have the potential to recover after cancer treatment. Because prompt control of the cancer was needed to treat the respiratory failure, empirical treatment with an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor was initiated before confirmation of EGFR-mutant adenocarcinoma, and the patient was successfully treated. Later, EGFR-mutant adenocarcinoma was confirmed.
Abstract
We herein describe a 70-year-old woman who presented with respiratory failure due to extensive lung adenocarcinoma. Despite advanced disease, care in the intensive care unit with ventilator support was performed because she was a newly diagnosed patient and was considered to have the potential to recover after cancer treatment. Because prompt control of the cancer was needed to treat the respiratory failure, empirical treatment with an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor was initiated before confirmation of EGFR-mutant adenocarcinoma, and the patient was successfully treated. Later, EGFR-mutant adenocarcinoma was confirmed.
참고문헌 (14)
- Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
- Adam AK, "Outcome and prognostic factors of lung cancer patients admitted to the medical intensive care unit", Eur Respir J, 31, pp.47~53 (2008)
- Lin YC, "Outcome of lung cancer patients with acute respiratory failure requiring mechanical ventilation", Respir Med, 98, pp.43~51 (2004)
- Soubani AO, "The outcome of medical intensive care for lung cancer patients: the case for optimism", J Thorac Oncol, 6, pp.633~638 (2011)
- Azoulay E, "Intensive care of the cancer patient: recent achievements and remaining challenges", Ann Intensive Care, 1, pp.5~ (2011)
- Cataldo VD, "Treatment of non-small-cell lung cancer with erlotinib or gefitinib", N Engl J Med, 364, pp.947~955 (2011)
- Kim ES, "Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial", Lancet, 372, pp.1809~1818 (2008)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Li C, "Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers", PLoS One, 6, pp.e28204~ (2011)
- Sun Y, "Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases", J Clin Oncol, 28, pp.4616~4620 (2010)
- Kim S, "High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer", PLoS One, 9, pp.e111693~ (2014)
- Darmon M, "Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy", Crit Care Med, 33, pp.2488~2493 (2005)
- Bosch-Barrera J, "Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma", Lung Cancer, 86, pp.102~104 (2014)
- Ahn HK, "Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer", J Thorac Oncol, 8, pp.250~253 (2013)